Resilience to Antibiotic-induced Obesogenic Microbiota: Discovering Mechanism of Microbiota Modulation
Recruiting · NCT06974994 · Interventional (participants receive a specific treatment) · Lead sponsor: Turku University Hospital
View the official record on ClinicalTrials.gov →Interventions studied
PlaceboSynbiotic Supplement
What this trial is about
The aim is to study whether the microbiota of children who are exposed to antibiotics at birth could be modified by synbiotic supplement and thereby reduce the risk of obesity, chronic diseases and respiratory tract infections. A total of 125 mother-child pairs will be recruited in this randomized, double-blind, placebo-controlled study. Infants are randomized to receive either a synbiotic supplement or a placebo for 2 months, after which their growth and morbidity will be monitored at the research clinic for 2 years.
Who can take part
Age range
2 Hours and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Pregnant women (n=125) and their newborn children who receive antibiotic treatment at delivery.
Exclusion criteria
- Chorioamnionitis
- Pre-eclampsia and hepatogestosis
- Suspected malformation or serious condition of the foetus and neonates
- Serious infection or other conditions not permitting breast milk feeding
Where it is running
1 location listed.
- Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku - Turku, Valitse Maakunta., Finland